Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells

Malignant Mesothelioma is a highly aggressive cancer, which is difficult to diagnose and treat. Here we describe the molecular, cellular and morphological characterization of a syngeneic system consisting of murine AB1, AB12 and AB22 mesothelioma cells injected in immunocompetent BALB/c mice, which...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2016-03, Vol.6 (1), p.22850, Article 22850
Hauptverfasser: Mezzapelle, Rosanna, Rrapaj, Eltjona, Gatti, Elena, Ceriotti, Chiara, Marchis, Francesco De, Preti, Alessandro, Spinelli, Antonello E., Perani, Laura, Venturini, Massimo, Valtorta, Silvia, Moresco, Rosa Maria, Pecciarini, Lorenza, Doglioni, Claudio, Frenquelli, Michela, Crippa, Luca, Recordati, Camilla, Scanziani, Eugenio, de Vries, Hilda, Berns, Anton, Frapolli, Roberta, Boldorini, Renzo, D’Incalci, Maurizio, Bianchi, Marco E., Crippa, Massimo P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Malignant Mesothelioma is a highly aggressive cancer, which is difficult to diagnose and treat. Here we describe the molecular, cellular and morphological characterization of a syngeneic system consisting of murine AB1, AB12 and AB22 mesothelioma cells injected in immunocompetent BALB/c mice, which allows the study of the interplay of tumor cells with the immune system. Murine mesothelioma cells, like human ones, respond to exogenous High Mobility Group Box 1 protein, a Damage-Associated Molecular Pattern that acts as a chemoattractant for leukocytes and as a proinflammatory mediator. The tumors derived from AB cells are morphologically and histologically similar to human MM tumors, and respond to treatments used for MM patients. Our system largely recapitulates human mesothelioma, and we advocate its use for the study of MM development and treatment.
ISSN:2045-2322
2045-2322
DOI:10.1038/srep22850